Abstract | BACKGROUND: METHODS: FINDINGS: In the period January, 1969, to December, 2008, we identified 1510 patients with HD, 471 with SBMA, and 3425 with HA. Cancer was diagnosed in 91 (6·0%) HD patients, 34 (7·2%) SBMA patients, and 421 (12·3%) HA patients. The standardised incidence ratios were 0·47 (95% CI 0·38-0·58), 0·65 (0·45-0·91), and 0·77 (0·70-0·85), respectively. Before diagnosis of polyQ disease, the risk of cancer was even lower. Cancer incidence and risk in the unaffected parents of patients with polyQ diseases were similar to those in the general population. INTERPRETATION: The consistently decreased incidence of cancer in patients with polyQ diseases suggests that a common mechanism protects against the development of cancer. This feature could be related to the polyQ-tract expansion seen in these diseases. Further studies are warranted to investigate the underlying mechanisms linking cancer and polyQ diseases. FUNDING: Swedish Cancer Society, Swedish Council for Working Life and Social Research.
|
Authors | Jianguang Ji, Kristina Sundquist, Jan Sundquist |
Journal | The Lancet. Oncology
(Lancet Oncol)
Vol. 13
Issue 6
Pg. 642-8
(Jun 2012)
ISSN: 1474-5488 [Electronic] England |
PMID | 22503213
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Adult
- Age Distribution
- Aged
- Databases, Factual
- Female
- Genetic Predisposition to Disease
(epidemiology)
- Humans
- Incidence
- Male
- Middle Aged
- Neoplasms
(epidemiology, genetics, physiopathology)
- Neurodegenerative Diseases
(epidemiology, genetics, physiopathology)
- Peptides
(genetics, metabolism)
- Registries
- Retrospective Studies
- Risk Assessment
- Sex Distribution
- Survival Analysis
- Sweden
(epidemiology)
|